Fig. 6
ExicFn+ transmitted resistance to oxaliplatin/5-FU by delivering hsa_circ_0004085 in vivo. A, B ExicFn+, ExicFn− or ExicEc+ were injected into CRC xenografts, and the mice were intraperitoneally injected with Oxa or 5-FU. The growth of subcutaneous tumors was measured and recorded, and the mice were finally sacrificed to harvest the subcutaneous tumors. C Subcutaneous tumors from different groups were weighed to assess their responsiveness to Oxa/5-FU. D Total RNA was extracted from subcutaneous tumor tissues of different groups, and the expression levels of hsa_circ_0004085 were determined by qRT-PCR. E H&E staining of subcutaneous tumors was carried out using hematoxylin (bluish violet) and eosin (red). IHC of subcutaneous tumors was carried out using ki-67 and c-caspase 3 antibodies, while IF was performed by using anti-PDI antibody (green). (*P < 0.05, **P < 0.01, ***P < 0.001, NS: not signifcant)